MNMD Mind Medicine
- 10.0050
- +0.4850+5.09%
Mind Medicine News
Press Release: MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update NEW YORK--(BUSINESS WIRE)--May 02, 2024-- Mind Medicine (MindMed) Inc. (NASDAQ
Psychedelic Drug Developers Could Benefit From NIH Funding for Chronic Pain
MindMed to Present at Upcoming May Medical Conferences
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
Mind Medicine Initiated at Outperform by Leerink Partners
Mind Medicine Initiated at Outperform by Leerink Partners
Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.
Mind Medicine (MNMD.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $20.00.
Leerink Partners Initiates Coverage On Mind Medicine With Outperform Rating, Announces Price Target of $20
Leerink Partners analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Outperform rating and announces Price Target of $20.
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. Shares of Simulations Plus, Inc. (NASDAQ:SLP) rose sharply in today's pre-market trading aft
MindMed to Present at Upcoming April Medical Conferences
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced
Mind Medicine Inc. Statement Inaccessible
MindMed Announces Voluntary Delisting From Cboe Canada
All Common shares will remain listed on Nasdaq Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Mind Medicine (NASDAQ:MNMD) Is Leading the Surge in Psychedelic Therapies
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementClinical-stage psychedelics biopharma c
The Next Great Biotech Boom Has Arrived
The U.S. Federal Drug Administration (FDA) has now designated psilocybin, a classical compound found in "magic mushrooms," as a "breakthrough...
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $75 price target.
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Analysis
Price Target
No Data
